Abstract
Objective: Based on pathogenesis of atrial fibrillation (AF), investigate the effects of precision drugs continuous therapy on AF cardioversion rate after radiofrequency catheter ablation. Methods: We included 1334 patients who underwent mitral valve replacement with bipolar radiofrequency ablation due to mitral valve disease with AF during June 2011 to July 2017. The data of clinical and related laboratory examinations at discharge and follow-up were recorded. All patients were treated with or without angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II-receptor blocker (ARB) drugs according to their conditions and doctor’s willingness. The heart rhythm was evaluated after treatment and follow-up of 6 months. Results: All 1162 cases were followed up, including 825 cases in mitral stenosis (MS) group, 337 cases in mitral regurgitation (MR) group. In MS group, left atrial diameter(LAD) and left ventricular diameter(LVD) of the patients taking ACEI and ARB were significantly lower (P < 0.05), and they can increase AF cardioversion rate from 79.1% of the control group to 83.7% and 82.8%, respectively (P = 0.03 and 0.04). In MR group, the patients with ACEI compared with control group, there were no significant differences in LAD, LVD, right atrial diameter (RAD), right ventricular diameter (RVD), left ventricular ejection fraction(LVEF), and left ventricular fractional shortening(LVFS) (P > 0.05); but ARB group, LAD, LVD decreased significantly (P < 0.05). And ACEI can increase AF cardioversion rate from 76.1% in the control group to 77.2% (P = 0.62), ARB to 81.6% (P = 0.02). Conclusion: It does improve AF cardioversion rate after radiofrequency catheter ablation that the precise anti-structural remodeling drugs continuous therapy was adopted based on the pathogenesis of AF.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Camm AJ, Savelieva I, Potpara T et al (2016) The changing circumstance of atrial fibrillation - progress towards precision medicine. J Intern Med 279(5):412–427
Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309–1321
Schaff HV (2015) Surgical ablation of atrial fibrillation--when, why, and how? N Engl J Med 372(15):1465–1467
Gillinov AM, Gelijns AC, Parides MK et al (2015) Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 372(15):1399–1409
Zhu X, Li Q, Li Y et al (2016) Analysis of bipolar radiofrequency ablation in treatment of atrial fibrillation associated with rheumatic heart disease. PLoS One 11(3):e0151248
Heijman J, Guichard JB, Dobrev D et al (2018) Translational challenges in atrial fibrillation. Circ Res 122(5):752–773
Roy D, Talajic M, Nattel S et al (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358(25):2667–2677
Chen L, Xiao Y, Ma R et al (2014) Bipolar radiofrequency ablation is useful for treating atrial fibrillation combined with heart valve diseases. BMC Surg 14:32
Yongjun Q, Huanzhang S, Wenxia Z et al (2015) From changes in local RAAS to structural remodeling of the left atrium: a beautiful cycle in atrial fibrillation. Herz 40(3):514–520
Qian Y, Liu Y, Tang H et al (2013) Circulating and local renin-angiotensin-aldosterone system express differently in atrial fibrillation patients with different types of mitral valvular disease. J Renin-Angiotensin-Aldosterone Syst 14(3):204–211
Qian Y, Shao H, Luo T et al (2008) Plasma angiotensin converting enzyme level and permanent atrial fibrillation with mitral valvular disease. Chin J Clin Thorac Cardiovasc Surg 39(11):674–677
Qian Y, Meng J, Tang H et al (2010) Different structural remodelling in atrial fibrillation with different types of mitral valvular diseases. Europace 12(3):371–377
Macle L, Khairy P, Weerasooriya R et al (2015) Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial. Lancet 386(9994):672–679
Verma A, Jiang CY, Betts TR et al (2015) Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 372(19):1812–1822
Schreiber D, Rostock T, Frohlich M et al (2015) Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ Arrhythm Electrophysiol 8(2):308–317
Khatib R, Joseph P, Briel M et al (2013) Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol 165(1):17–24
Gillis AM, Krahn AD, Skanes AC et al (2013) Management of atrial fibrillation in the year 2033: new concepts, tools, and applications leading to personalized medicine. Can J Cardiol 29(10):1141–1146
Al-Khatib SM, Allen LaPointe NM, Chatterjee R et al (2014) Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 160(11):760–773
Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18(11):1609–1678
Kirchhof P, Ammentorp B, Darius H et al (2014) Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace 16(1):6–14
Kirchhof P, Breithardt G, Aliot E et al (2013) Personalized management of atrial fibrillation: proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 15(11):1540–1556
Lafuente-Lafuente C, Valembois L, Bergmann JF et al (2015) Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev (3):Cd005049
Ausma J, van der Velden HM, Lenders MH et al (2003) Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation 107(15):2051–2058
Shenasa M, Soleimanieh M, Shenasa F (2012) Individualized therapy in patients with atrial fibrillation: new look at atrial fibrillation. Europace 14(Suppl 5):v121–v124
Roshanali F, Mandegar MH, Yousefnia MA et al (2009) Prevention of atrial fibrillation after coronary artery bypass grafting via atrial electromechanical interval and use of amiodarone prophylaxis. Interact Cardiovasc Thorac Surg 8(4):421–425
Komatsu T, Tachibana H, Sato Y et al (2009) Long-term efficacy of upstream therapy using angiotensin-converting enzyme inhibitors and statins in combination with antiarrhythmic agents for the treatment of paroxysmal atrial fibrillation. Int Heart J 50(4):465–476
Qian YJ, Xiao XJ, Yuan HS et al (2008) Combination pharmacological cardioversion of permanent atrial fibrillation in post-prosthetic mitral valve replacement outpatients: a novel approach for the treatment of atrial fibrillation. J Int Med Res 36(3):537–543
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Li, T., Qian, Y. (2020). Precise Drug Sequential Therapy Can Improve the Cardioversion Rate of Atrial Fibrillation with Valvular Disease after Radiofrequency Ablation. In: Huang, T. (eds) Precision Medicine. Methods in Molecular Biology, vol 2204. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0904-0_13
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0904-0_13
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0903-3
Online ISBN: 978-1-0716-0904-0
eBook Packages: Springer Protocols